Skip to main content Accessibility help
×
Home

Pharmaceutical industry's perspective on health technology assessment

  • Mickael Lothgren (a1) and Mark Ratcliffe (a1)

Abstract

This article presents the pharmaceutical industry's perspective on health technology assessment (HTA) with specific comments on the HTA systems in England and Wales, France, The Netherlands, and Sweden. The comments are focused on the following main themes: (i) The contributions of the HTA system to overall efficiency in the health-care system, (ii) HTA as a cost-driver for industry, patients, government, and society, and (iii) The various implementation barriers that currently exist for a successful implementation of HTA results.

Copyright

References

Hide All
ABPI. 2001 The costs of medicines—Good value for patients. ABPI Publication Brief. Ref: 528/01/6600X. Available at: www.abpi.org.uk. Accessed on February 17, 2003.
Berg M, van der Grinten T, Klazinga N. 2004 Technology assessments, priority setting, and appropriate care in Dutch health care. Int J Technol Assess Health Care. 20: 3543.
Carlsson P. 2004 Health technology assessment and priority setting for health policy in Sweden. Int J Technol Assess Health Care. 20: 4454.
Cookson R, McDaid D, Maynard A. 2001 Wrong SIGN, NICE mess: Is national guidance distorting allocation of resources. BMJ. 323: 743745.
Crump B, Drummond MF, Alexander S, Devaney C. 2000 Economic evaluation in the United Kingdom national health service. In: Graf von der Schulenburg J-M, ed. The influence of economic evaluation studies on health care decision-making: A European survey. Amsterdam: I.O.S. Press
Cutler DM, McCellan M. 2001 Is technological change in medicine worth it? Health Aff (Millwood). 20: 1129.
DiMasi JA, Caglarcan E, Wood-Armany M. 2001 Emerging role of pharmacoeconomics in the research and development decision-making process. Pharmacoeconomics. 19: 753766.
Drummond M, Cooke J, Walley T. 1997 Economic evaluation under managed care competition: Evidence from the UK. Soc Sci Med. 45: 583595.
Duthie T, Trueman P, Chancellor J, Diez L. 1999 Research into the use of health economics in decision making in the United Kingdom—Phase II. Is health economics for good or evil? Health Policy. 46: 143157.
Gafni A, Birch S. 2003 NICE methodological guidelines and decision making in the national health service in England and Wales. Pharmacoeconomics. 21: 149157.
Hoffmann C, Stoykova BA, Nixon J, et al. 2002 Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities. Value Health. 5: 7178.
Hutton J, Brown RE. 2002 Use of economic evaluation in decision-making: What needs to change? Value Health. 5: 6566.
Kleinke JD. 2001 The price of progress: Prescription drugs in the health care market. Health Aff (Millwood). 20: 4360.
NICE. Technical guidance for manufacturers and sponsors on making a submission to a technology appraisal. NICE March 2001.
Orvain J, Xerri B, Matillon Y. 2004 Overview of health technology assessment in France. Int J Technol Assess Health Care. 20: 2534.
Schubert F. 2002 Health technology assessment—The pharmaceutical Industry perspective. Int J Technol Assess Health Care. 18: 184191.
Sculpher M, Drummond M, O'Brien B. 2001 Effectiveness, efficiency, and NICE. A NICE start but evidence costs money. BMJ. 322: 943944.
Stevens A, Milne R. 2004 Health technology assessments in England and Wales. Int J Technol Assess Health Care. 20: 1124.
Towse A, Pritchard C. 2002 National institute for clinical excellence (NICE): Is economic appraisal working? Pharmacoeconomics. 20(Suppl 3): 95105.

Keywords

Pharmaceutical industry's perspective on health technology assessment

  • Mickael Lothgren (a1) and Mark Ratcliffe (a1)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed